Kringle Pharma
Kringle Pharma is a late-stage biopharmaceutical company dedicated to developing regenerative medicines based on recombinant human HGF protein. The company focuses on intractable and rare diseases, conducting clinical trials and aiming to bring breakthrough HGF protein therapies to patients worldwide. Their mission is to provide innovative treatments for difficult diseases and contribute to society.
Industries
Nr. of Employees
small (1-50)
Kringle Pharma
7-7-15 Asahi, Saihoku, Ibaraki City, Osaka 567-0085, Japan
Patents
Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
US-8927493-B2
View Details
Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
US-8927493-B2
View DetailsProducts
HGF protein development platform
Platform for production and development of recombinant human HGF protein as a therapeutic modality across multiple indications; used to generate clinical candidates and supply partners.
Recombinant HGF therapeutic — acute spinal cord injury (acute phase)
Recombinant HGF protein therapeutic developed for acute spinal cord injury; progressed through Phase I/II (POC obtained) and Phase III; received orphan drug designation in the U.S.
Recombinant HGF therapeutic — vocal fold scarring
Recombinant HGF protein therapeutic candidate for vocal fold scar; completed early-phase trials and conducting Phase III randomized placebo-controlled study.
Recombinant HGF therapeutic — ALS (amyotrophic lateral sclerosis)
Recombinant HGF protein candidate studied in Phase II (randomized, placebo-controlled) trials; primary and secondary endpoints did not show statistical significance and additional analyses are ongoing.
Recombinant HGF therapeutic — acute kidney injury
Recombinant HGF protein candidate investigated in Phase I a/b open-label dose-escalation studies with safety and pharmacokinetics confirmed; partner search ongoing.
HGF protein development platform
Platform for production and development of recombinant human HGF protein as a therapeutic modality across multiple indications; used to generate clinical candidates and supply partners.
Recombinant HGF therapeutic — acute spinal cord injury (acute phase)
Recombinant HGF protein therapeutic developed for acute spinal cord injury; progressed through Phase I/II (POC obtained) and Phase III; received orphan drug designation in the U.S.
Recombinant HGF therapeutic — vocal fold scarring
Recombinant HGF protein therapeutic candidate for vocal fold scar; completed early-phase trials and conducting Phase III randomized placebo-controlled study.
Recombinant HGF therapeutic — ALS (amyotrophic lateral sclerosis)
Recombinant HGF protein candidate studied in Phase II (randomized, placebo-controlled) trials; primary and secondary endpoints did not show statistical significance and additional analyses are ongoing.
Recombinant HGF therapeutic — acute kidney injury
Recombinant HGF protein candidate investigated in Phase I a/b open-label dose-escalation studies with safety and pharmacokinetics confirmed; partner search ongoing.
Services
Provision of pharmaceutical-grade HGF active substance to external developers for their clinical programs.
Joint research programs with universities and research institutions for new indications and early-stage discovery.
Provision of pharmaceutical-grade HGF active substance to external developers for their clinical programs.
Joint research programs with universities and research institutions for new indications and early-stage discovery.
Expertise Areas
- Regenerative medicine therapeutics development
- Recombinant protein biologics manufacturing
- Late-stage clinical trial management
- Rare disease drug development
Key Technologies
- Recombinant protein production
- HGF-based regenerative therapeutics
- Preclinical animal disease models
- Randomized double-blind placebo-controlled clinical trial methodology
News & Updates
Announcement of joint research with Kobe University on the application of HGF (hepatocyte growth factor) to Peroni disease.
Update on the second quarter financial results for the fiscal year ending September 2025.
Announcement of obtaining rare disease designation in the US for recombinant human HGF protein (KP-100IT) for acute spinal cord injury.
Q2 financial results briefing Q&A session update.
Announcement of joint research with Kobe University on the application of HGF (hepatocyte growth factor) to Peroni disease.
Update on the second quarter financial results for the fiscal year ending September 2025.
Announcement of obtaining rare disease designation in the US for recombinant human HGF protein (KP-100IT) for acute spinal cord injury.
Q2 financial results briefing Q&A session update.